Loading…
← CockpitCompetitor Analysis › 600513.SS Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A600513.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum laggard 12
Mkt cap
$496M
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$11.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-3.9 pp
WACC 5.6%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥11.82
1D-0.5%
1W-9.1%
1M-15.6%
3M-34.1%
6M-41.0%
YTD-35.5%
1Y-48.5%
ATR %4.3%
52w lowhigh63.4% off high

What Jiangsu Lianhuan Pharmaceutical does

Employees: 2,131

Jiangsu Lianhuan Pharmaceutical at a glance

Size Jiangsu Lianhuan Pharmaceutical (600513.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $496M, the 3718th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.82 on 18 Nov 2026.

Performance Over six months the shares fell 41.0%, against -12.8% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 14.3% over the last twelve months (peer median +9.8%); the operating margin is -0.3% (peer median 10.9%).

Valuation It trades at 1.8× enterprise value to sales against a peer median of 4.0× (3rd cheapest of 20).

Capital Return on invested capital runs 3.9 points below its cost of capital (5.6% WACC).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 88600513.SS 60
Six months, rebased to 100: Jiangsu Lianhuan Pharmaceutical against the median of its 20 peers (local-currency closes).

Jiangsu Lianhuan Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.96BCN¥2.70BCN¥2.14BCN¥2.15BCN¥1.94B
Revenue growth—+26%-1%+11%—
Gross profitCN¥940MCN¥888MCN¥1.02BCN¥999MCN¥1.01B
EBITDAn/aCN¥115MCN¥182MCN¥235MCN¥244M
Net income-CN¥48.6M-CN¥98.3MCN¥84.2MCN¥135MCN¥141M
Free cash flow-CN¥181M-CN¥286M-CN¥174M-CN¥40.0M-CN¥93.1M
Capital expenditureCN¥255MCN¥271MCN¥185MCN¥201MCN¥221M
Total debtCN¥1.90BCN¥1.72BCN¥942MCN¥788MCN¥740M

Quarterly statements and history in the cockpit →

Jiangsu Lianhuan Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+20%TKNO003090600222AARTIDRUGS0021071666GYRE603207301277GUJTHEMINDPEGTXRGNXHNSA600624SMSPHARMA600513.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Jiangsu Lianhuan Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×25×50×75×TKNO003090600222AARTIDRUGS0021071666603207301277300584GUJTHEMEGTX688373HNSA600624600513.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jiangsu Lianhuan Pharmaceutical is the large dot.

Jiangsu Lianhuan Pharmaceutical competitors and peer comparison

How Jiangsu Lianhuan Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jiangsu Lianhuan Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600513.SSPeer medianRank in peer set
1-month return-15.6%-0.8%2nd lowest of 21
6-month return-41.0%-12.8%lowest of 21
Distance from 52-week high-63.4%-34.8%lowest of 21
Revenue growth (TTM)+14.3%+9.8%8th highest of 20
Operating margin-0.3%10.9%8th lowest of 20
EV / Sales1.8×4.0×3rd cheapest of 20
ROIC minus cost of capital-3.9 pp-2.4 pp7th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%1.8×n/an/a
Alpha Teknova TKNOUnited States$496M+113%+15%-32%11.0×n/an/a
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%2.5×16.7%+4.4%
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%4.0×n/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%71.0×n/an/a
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%2.3×-6.1%+9.6%
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%4.9×n/an/a

Questions

Which companies are Jiangsu Lianhuan Pharmaceutical's closest peers?
The cockpit's peer set: Alpha Teknova (TKNO), Daewoong (003090.KS), Henan Taloph Pharmaceutical Stock (600222.SS), Aarti Drugs (AARTIDRUGS.NS), Shandong Wohua Pharmaceutical (002107.SZ), Tong Ren Tang Technologies (1666.HK), Gyre Therapeutics (GYRE), Shanghai Xiao Fang Pharmaceutical (603207.SS).
Is Jiangsu Lianhuan Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 1.8× against a peer median of 4.0×, 3rd cheapest of 20 in its peer set.
How has Jiangsu Lianhuan Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -41.0% against -12.8% for the median peer; over one year -48.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.